Sign inJoin waitlistJoin the waitlist

Frank Weinberg

Associate Director, Medical Scientist Training Program · University of Illinois College of Medicine at Chicago

Credentials: · · · · · · ·

History

University of Illinois College of Medicine at Chicago
Present

Hematology and Medical Oncology
University of Michigan
2017–2020
Internal Medicine
University of Michigan
2014–2017
Northwestern University
University of Illinois Urbana-Champaign
2010–2014

Research

Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity
Proceedings of the National Academy of Sciences of the United States of America · 2010 · First of 10 authors · 1,444 citations
Reactive Oxygen Species in the Tumor Microenvironment: An Overview
Review · Cancers · 2019 · First of 3 authors · 356 citations
Hypoxic activation of AMPK is dependent on mitochondrial ROS but independent of an increase in AMP/ATP ratio
Free Radical Biology and Medicine · 2009 · 282 citations

Nithya Ramnath
7 papers
CS
Constantine Stratakis
5 papers
EM
Elise Meoli
5 papers
Gregory Kalemkerian
4 papers
Mary Pasquinelli
4 papers
Ryan Nguyen
4 papers
Gr Budinger
3 papers
KG
Kurt Griffin
3 papers · 3 as a fellow
LK
Lawrence Kirschner
3 papers
Robert Dickson
3 papers
SS
Sotirios Stergiopoulos
3 papers
Edward Claflin
2 papers

Clinical trials

LUNG-05: Investigating Chemotherapy Effectiveness for Non-Small Cell Lung Cancer (NSCLC) Metastatic Patients
Principal investigator · Recruiting
University of Illinois at Chicago
2024–2026
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2025–2032
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
Site PI · Recruiting · Phase 3
ECOG-ACRIN Cancer Research Group
2024–2030
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2024–2039